First inhalable insuline

Abit old news, but nevertheless very good news for all diabetes patients who hate needles.
Exubera, the inhalable insulin developed by Nektar Therapeutics based in San Franciso, has been approved in the US and Europe in late January this year. Exubera, the first inhalale version of insulin, offers diabetics an alternative to traditional needle-based delivery.

The technique in which the drug is delivered aerosolized might be promising for the delivery of other drugs aswell, as stated by John Patton, Nektar's cofounder and chief scientific officer:

"Patton believes that Nektar's inhalation technology is widely applicable to delivering other peptides, noting that although big pharma has shown keen interest in the specificity and efficacy of peptides, most have struggled with formulations. "What we've really done with Exubera is shown that you can get peptides into the lung, without a needle," he says. "I think we're opening up the chance for medicines that have had a really tough haul."

"First inhalable insulin approved", Nature Biotechnology 24 (2006)